Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

SAN FRANCISCO, Nov. 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2013.

Cash and investments in marketable securities at September 30, 2013 were $208.6 million as compared to $302.2 million at December 31, 2012.

"Nektar continues to have a very productive year achieving significant milestones with both our partnered programs and proprietary pipeline," said Howard W. Robin, President and Chief Executive Officer of Nektar. "For naloxegol, the MAA in Europe and NDS in Canada are now accepted for filing and the NDA in the U.S. was submitted for filing in mid-September.  Naloxegol could be the first once-daily oral peripheral opioid antagonist approved to treat opioid-induced constipation.  BAX 855, Baxter's longer-acting PEGylated Factor VIII therapy, which is in Phase 3, remains on track for a 2014 BLA filing.  Finally, while I am disappointed that the results from the Phase 2 efficacy study for NKTR-181 were confounded by an unusual placebo response, we are working with our advisors and the FDA to design an optimal Phase 3 program, which should start by the middle of 2014." 

Revenue in the third quarter of 2013 was $60.9 million as compared to $18.4 million in the third quarter of 2012. Year-to-date revenue for 2013 was $117.8 million as compared to $60.0 million in the first nine months of 2012.  Revenues included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.5 million and $12.7 million in the third quarter and year-to-date for 2013, respectively, and $3.4 million in the third quarter and $6.9 million in the first nine months of 2012. This non-cash royalty revenue is offset by non-cash interest expense. The increases in revenue in the third quarter and first nine months of 2013 as compared to the same periods in
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Nopras Technologies ( www.nopras-tech.com ) has ... to the position of Director, Business Development ... from Bio-Investigations Ltd., a specialized global venture capital ... years ago, focused in the fields of human, ... graduate degrees in biology, biochemistry, and business from ...
(Date:11/18/2014)... , Nov. 18, 2014 ResMed (NYSE: ... the all-new S+, the world,s first non-contact, personal sleep monitoring ... in the United States and from ... by ResMed App now integrates with Apple HealthKit in iOS8 ... health and fitness. The user report can also be shared with ...
(Date:11/18/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the receipt of approval from the U.S. Food and ... IDEAL IMPLANT ® Saline-filled Breast Implant ... existing augmentation implants. The FDA approval of the IDEAL ... studies and data including a U.S. clinical trial that ...
Breaking Medicine Technology:Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 2Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 3ResMed's New S+ Consumer Sleep Monitor Now Integrates With Apple HealthKit 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3
(Date:11/18/2014)... As children head back to school and ... fall as the perfect time to refresh their looks ... County facial plastic surgeon, has observed a trend this ... Gallery of Cosmetic Surgery he has noticed an increase ... surgery procedures. , “Non-invasive cosmetic treatments give my ...
(Date:11/18/2014)... 2014 (HealthDay News) -- Hispanic women who,ve had at least ... type of heart trouble than those who,ve had fewer children ... researchers led by Shivani Aggarwal of Wake Forest School of ... from Chicago, Miami, New York City and San Diego. About ... six children. A type of heart trouble called ventricular ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... attack and stroke patients can safely take aspirin combined with ... combination won,t increase a patient,s risk of early death, according ... of the American Heart Association in Chicago. The report was ... Analysis of data from more than a dozen clinical ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... that help them track how many calories they consume each ... a popular one after their doctor recommended it did not ... idea of using such apps as weight-loss tools. Some participants ... of motivation varied, the researchers noted, and they added that ...
(Date:11/17/2014)... World Food Processing announced today that they will ... airing via RFD-TV 2nd QTR 2015. American Farmer airs ... World Food Processing is a sustainable solution for non-GMO ... provides a secure system, supplying non-GMO and organic products ... educate viewers about World Food Processing’s unparalleled capability to ...
Breaking Medicine News(10 mins):Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 3Health News:Certain Heart Dysfunction More Likely in Hispanic Women With Many Kids: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3Health News:Calorie-Tracking Apps May Not Help You Lose Weight 2Health News:Calorie-Tracking Apps May Not Help You Lose Weight 3Health News:American Farmer to Feature World Food Processing in 2015 Series 2
... WASHINGTON, July 1 Beginning July 6, Sharing,Miracles -- ... and inspirational stories of real patients -- will feature,four-time ... the,program will debut in Los Angeles on KCOP-TV at ... across the United States., Diver Greg Louganis won ...
... Accenx Technologies,Inc., is the premier sponsor of ... to Interoperability. The two-day event, held in Boston, ... Information Exchange (HIE) to the,next level., Accenx ... offering a Software as a Service (SaaS) solution ...
... health policy and administration in Penn State,s College of ... $4 million grant from the Robert Wood Johnson Foundation ... initiative, "Aligning Forces for Quality (AF4Q).", This grant is ... Robert Wood Johnson Foundation in 2007 and expands the ...
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,that ... with Triax,Aesthetics LLC for Pyratine-6(TM), all promotion, sales ... directly by the Company., Phil Rose, Senetek,s ...
... Glenn Hackbarth (MedPAC) and Bruce Bradley (General,Motors) - ... 1 The ABIM Foundation,will dedicate its efforts ... concepts,of medical professionalism and accountability in health care ... In addition, the Foundation announced that officers of ...
... Opus Healthcare Solutions, Inc.,a leading national ... Ray,Bechtold, CPA, as controller. Based at the ... overseeing all accounting and financial,administrative functions., ... http://www.newscom.com/cgi-bin/prnh/20080325/LATU040LOGO ), Bechtold joined Opus Healthcare ...
Cached Medicine News:Health News:'Sharing Miracles' Television Program to Feature Olympic Gold Medal-Winner Greg Louganis 2Health News:'Sharing Miracles' Television Program to Feature Olympic Gold Medal-Winner Greg Louganis 3Health News:'Sharing Miracles' Television Program to Feature Olympic Gold Medal-Winner Greg Louganis 4Health News:'Sharing Miracles' Television Program to Feature Olympic Gold Medal-Winner Greg Louganis 5Health News:'Sharing Miracles' Television Program to Feature Olympic Gold Medal-Winner Greg Louganis 6Health News:Accenx Technologies, a Premier Sponsor as the Educational Underwriters of the 3rd Annual World Congress Leadership Summit on The Road to Interoperability 2Health News:Researcher receives $4 million from RWJ Foundation to study health quality reform project 2Health News:Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM) 2Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Opus Healthcare Solutions Names Ray Bechtold as Controller 2
LASIK Retreatment Forceps - Also available in Titanium...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
Medicine Products: